Cells to Society: Year of the Nurse / Global Impact
This article provides a theoretical clarification of the concept "social cohesion" as it relates to health behaviors and outcomes, uncovering the critical attributes, antecedents, and consequences of social cohesion and reflecting on its future in health literature.
Read more
View More Research
...
Source: Johns Hopkins University and Health Systems Archive - December 11, 2020 Category: Nursing Source Type: news
New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with IMBRUVICA® remai...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very high ov...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discont...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Dr. Mallika Marshall On 2nd COVID Surge: ‘ Do Not Let Your Guard Down Now ’
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"4930940","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 3, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthwatch Seen On WBZ-TV Syndicated Local Coronavirus Dr. Mallika Marshall Source Type: news
Can Some Vaccines Reduce Your Alzheimer ’s Risk?
Could vaccines play a role in preventing Alzheimer’s disease? Researchers are looking at that question more broadly after finding that the flu and pneumonia vaccines might also help protect against the devastating memory loss of Alzheimer's disease. (Source: WebMD Health)
Source: WebMD Health - December 3, 2020 Category: Consumer Health News Source Type: news
US Presidential Election Part 3: President Trump ’s Legacy of Mismanagement of the Pandemic
Credit: Whitehouse.GovBy Farhang JahanpourOXFORD, Dec 1 2020 (IPS) Covid-19 is on track to be the deadliest and one of the most catastrophic epidemics since the 1918-1919 flu pandemic, which infected about 500 million people or one-third of the world’s population at the time. The number of deaths was estimated somewhere between 17 and 50 million, and possibly as high as 100 million worldwide.
The first observations of illness and mortality were documented in December 1917 at Camp Greene, North Carolina. To maintain morale, World War I censors minimized reports of casualties, but as newspapers in neutral Spain were free ...
Source: IPS Inter Press Service - Health - December 1, 2020 Category: International Medicine & Public Health Authors: Farhang Jahanpour Tags: Democracy Global Geopolitics Headlines Health North America TerraViva United Nations Source Type: news
On World AIDS Day, Those Who Fought the 1980s Epidemic Find Striking Differences and Tragic Parallels in COVID-19
More than three decades after the World Health Organization (WHO) launched the first World AIDS Day on Dec. 1, 1988, the world’s leading global health organization faces another public health crisis in COVID-19. On this World AIDS Day, those who raised awareness of HIV, the virus that causes AIDS, find devastating similarities and haunting differences in America’s response to both crises.
In 1981, scientists recorded the first cases of a rare pneumonia, usually found among immunosuppressed patients, among a group of gay men in Los Angeles, and noticed more cases appearing among gay men in San Francisco and New ...
Source: TIME: Health - December 1, 2020 Category: Consumer Health News Authors: Olivia B. Waxman Tags: Uncategorized COVID-19 feature HIV/AIDS Source Type: news
Fiji's vaccine program reduces childhood death and illness: study
(University of Melbourne) Fiji's national vaccine program against pneumonia, a serious lung condition, and rotavirus, a common disease which causes severe diarrhoea and vomiting, has reduced illness and death, new research shows. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 25, 2020 Category: Infectious Diseases Source Type: news
Moderna ’s COVID-19 Vaccine Is 94.5% Effective. Here’s What That Really Means
It’s wasn’t a typical Sunday morning for Dr. Stephen Hoge, president of the biotech company Moderna, and Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. They were at their respective homes in Massachusetts and Washington, D.C., waiting to to be let into a Zoom call to hear the results of the very first COVID-19 vaccine that was tested in people.
The hosts were members of the independent Data Safety Monitoring Board (DSMB) that is reviewing data involving all the COVID-19 vaccine candidates supported by the U.S. government’s Operation Warp Speed program, and Hoge a...
Source: TIME: Health - November 17, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
It's not just the vaccine. There are many causes for hope in the fight against Covid | Devi Sridhar
Scientists now have better tests and treatments, and are forging a clear pathway out of this global ordealOn 5 January 2020, the World Health Organization sent amemo to governments across the world reporting a small cluster of pneumonia-like cases in Wuhan, China. For many countries, the warning was like looking through a fog. Each month, the WHO picks up on average3000 potential disease signals and chooses 30 to investigate. In early January, global health scientists like myself were trying to assess the outbreak of“Wuhan pneumonia”, as it was then called, with huge gaps in our knowledge and considerable uncertainty: ...
Source: Guardian Unlimited Science - November 16, 2020 Category: Science Authors: Devi Sridhar Tags: Coronavirus Infectious diseases Science Medical research World news UK news Source Type: news
Covid update: OCD medication shown to improve symptoms of coronavirus
COVID-19 can ravage the body, causing breathlessness, pneumonia and the need for oxygen ventilators. With the vaccine still needing to jump through protocol hoops, researchers have been looking elsewhere. (Source: Daily Express - Health)
Source: Daily Express - Health - November 13, 2020 Category: Consumer Health News Source Type: news
Pfizer and BioNTech could make $13bn from coronavirus vaccine
Johnson& Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basisCoronavirus – latest updatesSee all our coronavirus coverageThe US drugmaker Pfizer and the German biotech firm BioNTech stand to bring in nearly $13bn ( £9.8bn) in global sales from theircoronavirus vaccine next year, which will be evenly split between the two companies, according to analysts at the US investment bank Morgan Stanley.Pfizer ’s half would be more than the US pharmaceutical group’s bestselling product, a pneumonia vaccine that generated $5.8bn last year.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 10, 2020 Category: Science Authors: Julia Kollewe Tags: Pfizer Pharmaceuticals industry Coronavirus Vaccines and immunisation Business World news Infectious diseases Science Source Type: news
Directed enhanced service specification for flu updated
An updated directed enhanced service specification (DES) for the seasonal flu and pneumococcal vaccination programme 2020/21 has been published. (Source: NHS Networks)
Source: NHS Networks - November 9, 2020 Category: UK Health Source Type: news
